Sildenafil in Hemodialysis Patients With Pulmonary Hypertension
Status:
Unknown status
Trial end date:
2019-02-28
Target enrollment:
Participant gender:
Summary
Sildenafil is a phosphodiesterase inhibitor that can exert a nitric oxide-mediated
vasodilation effect, so it's considered one of the preferred agents especially in hypoxia
induced pulmonary hypertension, can achieve pulmonary vasodilation by enhancing sustained
levels of cyclic guanosine monophosphate (cGMP) and nitric oxide.
Despite the potential burden of pulmonary hypertension in hemodialysis patients, such agent
like sildenafil has limited studies about optimum dose, safety and long term efficacy in End
stage renal disease patients on hemodialysis with pulmonary hypertension